Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 280619, Knoxville
University Of Tennessee Medical Center /ID# 279896, Knoxville
Baptist Memorial Hospital /ID# 281405, Memphis
e altri 2

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07365241

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sarah Cannon - Tennessee Oncology, Nashville

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT05983432

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

SCRI Oncology Partners, Nashville

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07325136

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

SCRI OP (Oncology Partners), Nashville

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07218146

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

SCRI Oncology Partners, Nashville

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT06646276

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Sarah Cannon Research Institute ( Site 7001), Nashville

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06780137

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

West Cancer Center & Research Institute, Germantown
University of Tennessee Medical Center, Knoxville

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT06712355

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

SCRI Oncology Partners, Nashville

In reclutamentoFase 1/2

Età da 18 a 100 · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT06726148

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Sarah Cannon Research Institute (SCRI), Nashville

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT07488923

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

Baptist Cancer Center, Memphis

In reclutamentoFase 1

Età da 18 a 99 · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT07531095

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

SCRI Oncology Partners, Nashville

In reclutamentoFase 2

Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT06095505

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT05592626

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

THE WEST CLINIC, PLLC dba West Cancer Center, Germantown

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06203210

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Tennessee Oncology, PLLC, Nashville

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 24 lug 2026 · NCT06931626

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Sarah Cannon Research Institute - Pharmacy, Nashville
SCRI Oncology Partners, Nashville

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT06131840

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Sarah Cannon Research Institute - Oncology Partners, Nashville

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 9 lug 2026 · NCT07174583

A Study of LY4175408 in Participants With Advanced Cancer

Sarah Cannon Research Institute, Nashville

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT07046923

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Research Site 136, Nashville

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 21 nov 2025 · NCT05914116

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.